Table 4 Completed clinical trials based on combination therapy with anti-PD-1/PD-L1 therapy for renal cell carcinoma (RCC) registered in ClinicalTrials.gov (June 2022)

Nivolumab Ipilimumab

2

118

Randomized

–

USA

Australia

Chile

NCT03029780

Nivolumab Ipilimumab

Sunitinib

Pazopanib

1

194

Non-Randomized

5.0 mg/kg

1 mg

50 mg

800 mg

Canada

USA

NCT01472081

X4P-001 Nivolumab

1/2

9

N/A

400 mg

240 mg

USA

NCT02923531

IL-2

Nivolumab

1/2

13

N/A

600,000 IU/kg

240 mg

USA

NCT02989714

Nivolumab

SBRT

2

69

N/A

240 mg

30 Gy

Italy

NCT03469713

Nivolumab Ipilimumab

Sunitinib

Pazopanib

2

200

Randomized

5.0 mg/kg

1 mg

50 mg

800 mg

France

NCT02960906

Nivolumab Ipilimumab

4

211

Non-Randomized

–

USA

NCT02982954

Nivolumab

CB-839

1/2

118

Non-Randomized

–

USA

NCT02771626

Nivolumab

Ipilimumab

SBRT

2

29

N/A

–

USA

NCT03065179

Ibrutinib Nivolumab

1/2

31

N/A

–

USA

NCT02899078

Tivozanib

Nivolumab

1/2

28

N/A

–

240 mg

France

NCT03136627

Varlilumab

Nivolumab

1/2

175

N/A

3 mg/kg

240 mg

USA

NCT02335918

Cabiralizumab

Nivolumab

1

313

Non-Randomized

2 mg/kg

3 mg/kg

USA

NCT02526017

Nivolumab

ABI-009

1/2

34

N/A

3 mg/kg

100 mg/m²

USA

NCT03190174

Pembrolizumab

Axitinib

1

52

N/A

2 mg/kg

3–5 mg

USA

NCT02133742

Bevacizumab

Pembrolizumab

1/2

61

Non-Randomized

10 mg

200 mg

USA

NCT02348008

Pembrolizumab Ipilimumab

or

PegIFN-2b

1/2

295

Randomized

200 mg

50–100 mg

–

UK

NCT02089685

Pazopanib

Pembrolizumab

1

42

Randomized

200 mg

10 mg/kg

USA

NCT02014636

Pembrolizumab

Radiotherapy

1/2

30

N/A

200 mg

18–20 Gy

Australia

NCT02855203

Pembrolizumab

INCB050465

Itacitinib

1

159

Randomized

200 mg

–

–

USA

NCT02646748

Pembrolizumab

INCB024360

1/2

444

Non-Randomized

25 mg

–

USA

NCT02178722

Atezolizumab

Bevacizumab

3

915

Randomized

1200 mg

15 mg/kg

International

NCT02420821

Atezolizumab

Bevacizumab

2

305

Randomized

1200 mg

15 mg/kg

International

NCT01984242

Atezolizumab

Bevacizumab

RO6874281

1

69

Randomized

840 mg

10 mg/kg

5 mg

International

NCT03063762

Ciforadenant

Atezolizumab

1

502

Randomized

100–200 mg

–

Canada

USA

Australia

NCT02655822

Avelumab

Cabozantinib

1

12

N/A

10 mg/kg

20–60 mg

USA

NCT03200587

Avelumab

Axitinib

1

55

N/A

5–10 mg/kg

3–5 mg

Japan

USA

UK

NCT02493751

Durvalumab

Tremelimumab

1

29

N/A

–

–

USA

NCT02762006

MEDI0680

Durvalumab

Nivolumab

1/2

97

Randomized

0.1–20 mg/kg

3–10 mg/kg

240 mg

International

NCT02118337

PolyICLC

Durvalumab

Tremelimumab

1/2

58

Non-Randomized

–

USA

NCT02643303